5-Lipoxygenase Inhibitor [EPC] - N0000175956

  1. Home
  2. Pharmacologic Class Index
  3. 5-Lipoxygenase Inhibitor [EPC] - N0000175956

Pharmacologic Class Information

Pharmacologic Code N0000175956
Pharmacologic Name 5-Lipoxygenase Inhibitor
Pharmacologic Uses
  • 5-lipoxygenase inhibitor
Pharmacologic Concept Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions:
  • A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication.
  • A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

NDC Products with 5-Lipoxygenase Inhibitor

The table contains 7 products whose active ingredient are classified under the same pharmacologic class 5-Lipoxygenase Inhibitor [EPC].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
10122-901Zyflo Non-Proprietary Name: ZileutonTabletOralChiesi Usa, Inc.ACTIVE
31722-044Zileuton Non-Proprietary Name: ZileutonTablet, Film Coated, Extended ReleaseOralCamber Pharmaceuticals, Inc.ACTIVE
49884-723Zileuton Non-Proprietary Name: ZileutonTablet, Multilayer, Extended ReleaseOralPar Pharmaceutical, Inc.ACTIVE
51407-741Zileuton Non-Proprietary Name: ZileutonTablet, Multilayer, Extended ReleaseOralGolden State Medical Supply, Inc.ACTIVE
64380-189Zileuton Non-Proprietary Name: ZileutonTablet, Multilayer, Extended ReleaseOralStrides Pharma Science LimitedACTIVE
64980-206Zileuton Non-Proprietary Name: ZileutonTablet, Extended ReleaseOralRising Pharmaceuticals, Inc.ACTIVE
69339-130Zileuton Non-Proprietary Name: ZileutonTablet, Multilayer, Extended ReleaseOralDash Pharmaceutical LlcACTIVE